Spermosens

The excellent collaboration between Spermosens and RMC has played a key role in exceeding recruitment goals, with couples now being enrolled at a faster pace than initially expected. The next generation JUNO-Checked technology is performing consistently which indicates good quality of clinical data.

Given the encouraging performance and recruitment progress, Spermosens is now aiming at interim results from the clinical trial by the end of the year, provided that the current pace and positive trajectory continue. These results will provide important insights into the technology's ability to predict the male fertility potential.

Tore Duvold, CEO of Spermosens, comments: “We are delighted with the progress of the clinical study and our collaboration with RMC. The rapid recruitment of couples, along with the strong performance of our next generation JUNO-Checked, strengthens our belief in the diagnostic potential of this technology. If the study continues to progress as we have seen so far, we anticipate being able to share interim results before year-end, bringing us a step closer to offering a new solution for male infertility diagnostics.”

Maria Liljander, CSO of Spermosens, comments: "The progress with recruitment at RMC, combined with the good performance of our JUNO-Checked technology, are highly promising. Working closely with the clinical team on-site allows us to monitor developments in real-time and ensure smooth execution. The early data we're seeing is encouraging, and I'm hopeful that we can share the interim results by year-end. This is a crucial step toward validating the technology and demonstrating its diagnostic potential for male fertility."

The JUNO-Checked technology addresses a major gap in male infertility diagnostics by measuring the sperm’s capacity to bind to the egg, providing a more comprehensive understanding of sperm function. This could significantly enhance treatment personalization and improve success rates for couples undergoing fertility treatment.

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com